Long-term effect of low-density lipoprotein apheresis in patients with heterozygous familial hypercholesterolemia

Therapeutic Apheresis

Volumn 7, Issue 4, 2003, Pages 402-407

  Higashikata, Toshinori ^a   Mabuchi, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Coronary artery disease; Dextran sulfate cellulose; Familial hypercholesterolemia; LDL apheresis; Statin

Indexed keywords

ATORVASTATIN; CELLULOSE; COLESTYRAMINE; DEXTRAN SULFATE; FLUINDOSTATIN; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ANGIOGRAPHY; APHERESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HUMAN; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

ANTILIPEMIC AGENTS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; PLASMAPHERESIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0042817880     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00074.x     Document Type: Review

References (25)

1. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the millenium, triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
2. Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am J Cardiol 1998;82:3Q-12Q.
3. Goldstein JL, Hobbs HH et al. Familial hypercholesterolemia. In: Scriver, CR, Beaudet, AL, Sly, WS, Valle, D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill 2001, 2863-913.
4. Mabuchi H, Koizumi L, Shimizu M, Takeda R, the Hokuriku FH-CHD Study Group. Development of coronary heart disease in familial hypercholesterolemia. Circulation 1989;79:225-32.
5. Mabuchi H, Sakai T, Sakai Y et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med 1983;308:609-13.
6. Witztum JL, Simmons D, Steinberg D et al. Intensive combination drug therapy of familial hypercholesterolemia with lovastatin, probucol, and colestipol hydrochloride. Circulation 1989;79:16-28.
7. Mabuchi H. Use of LDL-apheresis in the management of familial hypercholesterolemia. Curr Opin Lipidol 1990;1:43-7.
8. Kajinami K, Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipidol 1999;9:401-6.
9. Yokoyama S, Hayashi R, Kikkawa T et al. Specific adsorbent of apolipoprotein-B-containing lipoproteins for plasmapheresis. Characterization and experimental use in hypercholesterolemic rabbits. Arteriosclerosis 1984;4:276-82.
10. Mabuchi H, Michishita I, Takeda M et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 1987;68:19-25.
11. Tatami R, Inoue N, Itoh H et al. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992;95:1-13.
12. Waidner T, Franzen D, Voelker W et al. The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Invest 1994;72:858-63.
13. Thompson GR, Maher VMG, Mathews S et al. Familial Hypercholesterolemia Regression Study: a randomized trial of low-density lipoprotein apheresis. Lancet 1995;345:811-6.
14. Richter WO, Donner MG, Höfling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998;47:863-8.
15. Gordon BR, Kelsey SF, Dau PC et al. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am J Cardiol 1998;81:407-11.
16. Mabuchi H, Koizumi J, Shimizu M et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am J Cardiol 1998;82:1489-95.
17. Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 1999;144:409-17.
18. Matsuzaki M, Hiramori K, Imaizumi T et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia, the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002;40:220-7.
19. Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
20. Koga N, Watanabe K, Kurashige Y, Sato T, Hiroki T. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolaemic patients. J Intern Med 1999;246:35-43.
21. Kroon AA, van der Asten WNJC, Stalenhoef AFH. Effect of apheresis on low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-54.
22. Hennerici M, Kleophas W, Gries FA. Regression of carotid plaques during low density lipoprotein cholesterol elimination. Stroke 1991;22:989-92.
23. Mabuchi H, Fujita H, Michishita I et al. Effects of CS-514, and inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL) -apheresis. Atherosclerosis 1988;72:183-8.
24. Geiss HC, Parhofer G, Schwandt P. Atorvastatin compared with simvastatin in patients with severe hypercholesterolemia treated by regular LDL apheresis. J Intern Med 1999;245:47-55.
25. Dräger LJ, Julius U, Kracnzle K et al. DALI - the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998;28:994-1002.